Literature DB >> 32988988

Place and causes of acute cardiovascular mortality during the COVID-19 pandemic.

Jianhua Wu1,2, Mamas A Mamas3, Mohamed O Mohamed4, Chun Shing Kwok5, Chris Roebuck6, Ben Humberstone7, Tom Denwood6, Thomas Luescher8, Mark A de Belder9, John E Deanfield10, Chris P Gale11,12,13.   

Abstract

OBJECTIVE: To describe the place and causes of acute cardiovascular death during the COVID-19 pandemic.
METHODS: Retrospective cohort of adult (age ≥18 years) acute cardiovascular deaths (n=5 87 225) in England and Wales, from 1 January 2014 to 30 June 2020. The exposure was the COVID-19 pandemic (from onset of the first COVID-19 death in England, 2 March 2020). The main outcome was acute cardiovascular events directly contributing to death.
RESULTS: After 2 March 2020, there were 28 969 acute cardiovascular deaths of which 5.1% related to COVID-19, and an excess acute cardiovascular mortality of 2085 (+8%). Deaths in the community accounted for nearly half of all deaths during this period. Death at home had the greatest excess acute cardiovascular deaths (2279, +35%), followed by deaths at care homes and hospices (1095, +32%) and in hospital (50, +0%). The most frequent cause of acute cardiovascular death during this period was stroke (10 318, 35.6%), followed by acute coronary syndrome (ACS) (7 098, 24.5%), heart failure (6 770, 23.4%), pulmonary embolism (2 689, 9.3%) and cardiac arrest (1 328, 4.6%). The greatest cause of excess cardiovascular death in care homes and hospices was stroke (715, +39%), compared with ACS (768, +41%) at home and cardiogenic shock (55, +15%) in hospital. CONCLUSIONS AND RELEVANCE: The COVID-19 pandemic has resulted in an inflation in acute cardiovascular deaths, nearly half of which occurred in the community and most did not relate to COVID-19 infection suggesting there were delays to seeking help or likely the result of undiagnosed COVID-19. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  acute coronary syndromes; stroke

Mesh:

Year:  2020        PMID: 32988988      PMCID: PMC7523172          DOI: 10.1136/heartjnl-2020-317912

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


Introduction

Cardiovascular disease (CVD) is one of the most prevalent underlying condition associated with increased mortality from COVID-19 infection.1–5 Yet, we and others have shown a substantial reduction in presentations to hospitals with acute cardiovascular (CV) conditions including acute coronary syndrome, heart failure, cardiac arrhythmia and stroke during the pandemic.6–11 This would be expected to result in a much higher number of deaths, unless there has been an actual decrease in the incidence of these acute conditions. The detailed impact on mortality from acute CVD has, however, not been studied at national level. We now report, with high temporal resolution, CV-specific mortality during COVID-19 in England and Wales. In particular, we have evaluated the location of CV deaths (eg, hospitals, home or care homes), their relation to COVID-19 infection and the specific CV fatal events that contributed directly to death. This information is vital for the understanding of healthcare policy during the pandemic and to assist governments around the world reorganise healthcare services.

Methods

Data and deaths

The analytical cohort included all certified and registered deaths in England and Wales ≥18 years of age, between 1 January 2014 and 30 June 2020 recorded in the Civil Registration Deaths Data of the Office for National Statistics (ONS) of England and Wales.12

Acute CV death

The primary analysis was based on any of the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) codes corresponding to the immediate cause of death and contributed causes registered, as stated on the medical certificate of cause of death (MCCD). The MCCD is completed by the doctor who attended the deceased during their last illness within 5 days unless there is to be a coroner’s postmortem or an inquest. CV events directly leading to death (herein called acute CV deaths) were categorised as acute coronary syndrome (ST-elevation myocardial infarction (STEMI), non-STEMI, type 2 myocardial infarction, reinfarction) abbreviated as acute coronary syndrome, heart failure, cardiac arrest, ventricular tachycardia (VT) and/or ventricular fibrillation (VF), stroke (acute ischaemic stroke, acute haemorrhagic stroke, other non-cerebral strokes, unspecified stroke), cardiogenic shock, pulmonary embolism, deep venous thrombosis, aortic disease (aortic aneurysm rupture and aortic dissection) and infective endocarditis (online supplemental table 1). ICD-10 codes ‘U071’ (confirmed) and ‘U072’ (suspected) were used to identify whether a death was related to COVID-19 infection on any part of the MCCD. The place of death as recorded on the MCCD was classified as home, care home and hospice, and hospital.

Statistical analyses

Baseline characteristics were described using numbers and percentages for categorical data. Data were stratified by COVID-19 status (suspected or confirmed, not infected), age band (<50, 50–59, 60–69, 70–79, 80+ years)), sex and place of death (home, hospital, care home or hospice). The number of daily deaths was presented using a 7-day simple moving average (the mean number of daily deaths for that day and the preceding 6 days) from 1 February 2020 up to and including 30 June 2020, adjusted for seasonality. The expected daily deaths from 1 February 2020 up to and including 30 June 2020 were estimated using Farrington surveillance algorithm for daily historical data between 2014 and 2020.13 The algorithm used overdispersed Poisson generalised linear models with spline terms to model trends in counts of daily death, accounting for seasonality. The number of non-COVID-19 CV deaths each day from 1 February 2020 were subtracted from the estimated expected daily deaths in the same time period to create a zero historical baseline. Deaths above this baseline maybe interpreted as excess mortality, which were calculated as the difference between the observed daily deaths and the expected daily deaths. Negative values, where the observed deaths fell below the expected deaths, were set to zero. The rate of excess deaths was derived from dividing excess mortality by the sum of the expected deaths between 2 March 2020 and 30 June 2020. For the categories of acute CV death, the ICD-10 code on the MCCD was counted only once per deceased. Thus, the overall rate of acute CV death represents the number of people with a direct CV cause of death. Given that, people may have more than one of the predefined CV events leading to death, analyses for each of the predefined CV categories represent the number of events (not people) per category. For the purposes of this investigation, CVD that contributed, but did not directly lead to death were excluded from the analyses. All tests were two sided and statistical significance considered as p<0.05. Statistical analyses were performed in R V.4.0.0, and the Farrington surveillance algorithm was fitted using R package ‘surveillance’.

Results

Between 1 January 2014 and 30 June 2020, there were 3 450 381 deaths from all causes among adults. The proportion of deaths increased with increasing age band and there were 1 752 908 (50.8%) in women (table 1). People dying from any of the directly contributing CV categories accounted for 587 225 (17.0%) of all deaths, of which 6.0% had at least two of the predefined CV categories that directly contributed to death. Most deaths occurred in hospital (63.0%) followed by home (23.5%) and at care home (13.5%).
Table 1

Acute CV deaths before and after 2 March 2020, by COVID-19 status

Acute CV deaths before 2 March 2020Non-COVID-19 acute CV deaths after 2 March 2020COVID-19 acute CV deaths after 2 March 2020Acute CV deaths after 2 March 2020
Totaln=5 58 256n=27 489n=1480n=28 969
Sex
 Men288 834 (51.7)14 602 (53.1)855 (57.8)15 457 (53.4)
 Women269 422 (48.3)12 887 (46.9)625 (42.2)13 512 (46.6)
Age category (years)
 18–4920 213 (3.6)1096 (4.0)57 (3.9)1153 (4.0)
 50–5932 671 (5.9)1863 (6.8)124 (8.4)1987 (6.9)
 60–6964 763 (11.6)3415 (12.4)212 (14.3)3627 (12.5)
 70–79128 862 (23.1)6718 (24.4)379 (25.6)7097 (24.5)
 80+311 747 (55.8)14 397 (52.4)708 (47.8)15 105 (52.1)
Region
 North East24 119 (5.1)1354 (4.9)61 (4.1)1415 (4.9)
 North West65 446 (13.7)3671 (13.4)198 (13.4)3869 (13.4)
 Yorkshire and the Humber48 031 (10.1)2700 (9.8)136 (9.2)2836 (9.8)
 East Midlands36 544 (7.7)2172 (7.9)91 (6.1)2263 (7.8)
 West Midlands51 891 (10.9)3022 (11.0)193 (13.0)3215 (11.1)
 East of England49 032 (10.3)2819 (10.3)136 (9.2)2955 (10.2)
 London50 846 (10.7)2903 (10.6)268 (18.1)3171 (10.9)
 South East71 515 (15.0)4169 (15.2)239 (16.1)4408 (15.2)
 South West49 524 (10.4)3027 (11.0)78 (5.3)3105 (10.7)
 Wales29 311 (6.2)1651 (6.0)80 (5.4)1731 (6.0)
Place of death*
 Home128 407 (23.5)8654 (32.2)105 (7.1)8759 (30.9)
 Care home and hospice73 971 (13.5)4271 (15.9)174 (11.8)4445 (15.7)
 Hospital345 087 (63.0)13 929 (51.9)1196 (81.1)15 125 (53.4)
Underlying acute CV cause of deaths†
 Stroke199 730 (35.8)7789 (36.2)501 (38.3)8290 (36.3)
 Acute coronary syndrome140 316 (25.1)5256 (24.4)276 (21.1)5532 (24.2)
 Heart failure122 138 (21.9)5048 (23.5)232 (17.8)5280 (23.1)
 Pulmonary embolism50 744 (9.1)1844 (8.6)223 (17.1)2067 (9.1)
 Cardiac arrest29 255 (5.2)954 (4.4)83 (6.4)1037 (4.5)
 Aortic diseases28 446 (5.1)888 (4.1)4 (0.3)892 (3.9)
 Infective endocarditis13 499 (2.4)648 (3.0)28 (2.1)676 (3.0)
 Cardiogenic shock6596 (1.2)205 (1.0)13 (1.0)218 (1.0)
 VT and VF2356 (0.4)73 (0.3)3 (0.2)76 (0.3)
 Deep vein thrombosis480 (0.1)74 (0.3)2 (0.2)76 (0.3)

*The numbers do not add up to the total deaths due to missingness (1.9%).

†Listed CV-related conditions may not add up to 100% because some deaths may have multiple CV-related conditions.

CV, cardiovascular; VF, ventricular fibrillation; VT, ventricular tachycardia.

Acute CV deaths before and after 2 March 2020, by COVID-19 status *The numbers do not add up to the total deaths due to missingness (1.9%). †Listed CV-related conditions may not add up to 100% because some deaths may have multiple CV-related conditions. CV, cardiovascular; VF, ventricular fibrillation; VT, ventricular tachycardia.

Acute CV deaths after 2 March 2020

Following the first UK death from COVID-19 on 2 March 2020, there were 28 969 acute CV deaths of which 5.1% related to COVID-19 (7.9% suspected; 92.1% confirmed), and an excess acute CV mortality of 2085 (a proportional increase of 8%) compared with the expected historical average in the same time period of the year. COVID-19 deaths accounted for 1307 (71.0%) of all excess deaths after this date (figure 1, table 2). Qualitatively, excess acute CV mortality began in late March 2020 and peaked in early April 2020. While hospital remained the most frequent place of acute CV death, there were proportionally fewer deaths in hospital (53.4% vs 63.0%) and more at home (30.9% vs 23.5%) and in care homes (15.7% vs 13.5%) (table 1). Moreover, deaths at home saw the greatest increase in excess acute CV deaths (a proportional increase of 35%), followed by deaths at care homes (a proportional increase of 32%) and there was no excess acute CV deaths in hospital (table 2). The number of excess acute CV deaths were higher more among men than women (1182 vs 948; a proportional increase of 8% vs 7%) and were highest in the age category 18–49 years (176, a proportional increase of 17%) (table 2). The most frequent cause of acute CV death during the COVID-19 pandemic was stroke (35.6%), followed by acute coronary syndrome (24.5%), heart failure (23.4%), pulmonary embolism (9.3%) and cardiac arrest (4.6%) (table 1). Moreover, deep vein thrombosis demonstrated the greatest increase in excess acute CV death (20, a proportional increase of 23%), followed by pulmonary embolism (437, a proportional increase of 19%) and cardiogenic shock (54, a proportional increase of 14%) (figure 2, table 2).
Figure 1

Time series of acute cardiovascular (CV) deaths, by place of death. The number of daily CV deaths is presented using a 7-day simple moving average (indicating the mean number of daily CV deaths for that day and the preceding 6 days) from 1 February 2020 up to and including 30 June 2020, adjusted for seasonality. The number of non-COVID-19 excess CV deaths each day from 1 February 2020 were subtracted from the expected daily death estimated using Farrington surveillance algorithm in the same time period. The green line is a zero historical baseline. The red line represents daily COVID-19 CV death from 2 March to 30 June 2020; the purple line represents excess daily non-COVID-19 CV death from 2 March to 30 June 2020 and the blue line represents the total excess daily CV death from 1 February to 30 June 2020.

Table 2

COVID-19 related and total excess acute CV deaths

Excess acute CV deaths
COVID-19 relatedTotal*
Total1480 (+5%)2085 (+8%)
Sex
 Men855 (+6%)1182 (+8%)
 Women625 (+5%)948 (+7%)
Age category (years)
 18–4957 (+5%)176 (+17%)
 50–59124 (+7%)248 (+14%)
 60–69212 (+7%)468 (+15%)
 70–79379 (+6%)688 (+11%)
 80+708 (+5%)734 (+5%)
Region
 North East61 (+4%)70 (+5%)
 North West198 (+5%)159 (+4%)
 Yorkshire and the Humber136 (+5%)161 (+6%)
 East Midlands91 (+4%)117 (+5%)
 West Midlands193 (+6%)309 (+10%)
 East of England136 (+5%)153 (+5%)
 London268 (+9%)323 (+11%)
 South East239 (+5%)187 (+4%)
 South West78 (+3%)189 (+6%)
 Wales80 (+4%)55 (+3%)
Place of death†
 Home105 (+2%)2279 (+35%)
 Care home and hospice174 (+5%)1095 (+32%)
 Hospital1196 (+7%)50 (+0%)
Underlying acute CV cause of deaths
 Stroke562 (+6%)825 (+8%)
 Acute coronary syndrome318 (+5%)603 (+9%)
 Heart failure273 (+4%)552 (+9%)
 Pulmonary embolism251 (+11%)437 (+19%)
 Cardiac arrest93 (+6%)28 (+2%)
 Aortic diseases4 (+0%)25 (+2%)
 Infective endocarditis32 (+4%)92 (+11%)
 Cardiogenic shock14 (+4%)54 (+14%)
 VT and VF4 (+2%)23 (+12%)
 Deep vein thrombosis2 (+2%)20 (+23%)

*The excess death in subcategories may not add up to the total excess deaths due to estimation and rounding error when comparing to the respective historical average.

†The excess death in place of death do not add up to the total excess deaths due to setting those daily deaths below the expected historical average to zeros in the respective subgroup.

CV, cardiovascular; VF, ventricular fibrillation; VT, ventricular tachycardia.

Figure 2

Time series of acute cardiovascular (CV) deaths by COVID-19, by cause of death. The number of daily CV deaths is presented using a 7-day simple moving average (indicating the mean number of daily CV deaths for that day and the preceding 6 days) from 1 February 2020 up to and including 30 June 2020, adjusted for seasonality. The number of non-COVID-19 excess CV deaths each day from 1 February 2020 were subtracted from the expected daily death estimated using Farrington surveillance algorithm in the same time period. The green line is a zero historical baseline. The red line represents daily COVID-19 CV death from 2 March to 30 June 2020; the purple line represents excess daily non-COVID-19 CV death from 2 March to 30 June 2020 and the blue line represents the total excess daily CV death from 1 February to 30 June 2020. VF, ventricular fibrillation; VT, ventricular tachycardia.

Time series of acute cardiovascular (CV) deaths, by place of death. The number of daily CV deaths is presented using a 7-day simple moving average (indicating the mean number of daily CV deaths for that day and the preceding 6 days) from 1 February 2020 up to and including 30 June 2020, adjusted for seasonality. The number of non-COVID-19 excess CV deaths each day from 1 February 2020 were subtracted from the expected daily death estimated using Farrington surveillance algorithm in the same time period. The green line is a zero historical baseline. The red line represents daily COVID-19 CV death from 2 March to 30 June 2020; the purple line represents excess daily non-COVID-19 CV death from 2 March to 30 June 2020 and the blue line represents the total excess daily CV death from 1 February to 30 June 2020. Time series of acute cardiovascular (CV) deaths by COVID-19, by cause of death. The number of daily CV deaths is presented using a 7-day simple moving average (indicating the mean number of daily CV deaths for that day and the preceding 6 days) from 1 February 2020 up to and including 30 June 2020, adjusted for seasonality. The number of non-COVID-19 excess CV deaths each day from 1 February 2020 were subtracted from the expected daily death estimated using Farrington surveillance algorithm in the same time period. The green line is a zero historical baseline. The red line represents daily COVID-19 CV death from 2 March to 30 June 2020; the purple line represents excess daily non-COVID-19 CV death from 2 March to 30 June 2020 and the blue line represents the total excess daily CV death from 1 February to 30 June 2020. VF, ventricular fibrillation; VT, ventricular tachycardia. COVID-19 related and total excess acute CV deaths *The excess death in subcategories may not add up to the total excess deaths due to estimation and rounding error when comparing to the respective historical average. †The excess death in place of death do not add up to the total excess deaths due to setting those daily deaths below the expected historical average to zeros in the respective subgroup. CV, cardiovascular; VF, ventricular fibrillation; VT, ventricular tachycardia.

COVID-19-related acute CV deaths

Compared with deaths prior to 2 March 2020, COVID-19 related acute CV deaths were more likely to occur in hospital (81.1% vs 63.0%), much less at home (7.1% vs 23.5%) and remained of similar proportions to non-COVID-19-related acute CV deaths in care homes (13.5% vs 11.8%). The rate of COVID-19-related excess CV deaths was higher in hospitals than care homes (a proportional increase of 7% vs +5%) and less at home (a proportional increase of 2%). Excess COVID-19-related acute CV deaths occurred in similar proportions for men and women (a proportional increase of 6% vs 5%), and the rate of excess COVID-19-related acute CV deaths was comparable across the age bands (table 2). The greatest proportional increase of excess COVID-19-related acute CV death was due to pulmonary embolism (251, a proportional increase of 11%) followed by stroke (562, a proportional increase of 6%), acute coronary syndrome (318, a proportional increase of 5%), cardiac arrest (93, a proportional increase of 6%) and heart failure (273, a proportional increase of 4%) (figure 2, table 2).

Place and cause of death after 2 March 2020

The most frequent causes of excess acute CV death in care homes and hospices were stroke (715, a proportional increase of 39%) and heart failure (227, a proportional increase of 25%), which compared with acute coronary syndrome (768, a proportional increase of 41%) and heart failure (734, a proportional increase of 33%) at home, and pulmonary embolism (155, a proportional increase of 13%) and cardiogenic shock (55, a proportional increase of 15%) in hospital (figure 3, table 3). For stroke, acute coronary syndrome, heart failure and cardiac arrest, the numbers of deaths in hospital were lower than the historical baseline (figure 3).
Figure 3

Time series of acute cardiovascular (CV) deaths by cause of death and place of death. The number of daily CV deaths is presented using a 7-day simple moving average (indicating the mean number of daily CV deaths for that day and the preceding 6 days) from 1 February 2020 up to and including 30 June 2020, adjusted for seasonality. The number of non-COVID-19 excess CV deaths each day from 1 February 2020 were subtracted from the expected daily death estimated using Farrington surveillance algorithm in the same time period. The green line is a zero historical baseline. The red line represents excess daily death at hospital; the purple line represents excess daily CV death at care home and hospice and the blue line represents excess daily CV death at home. VF, ventricular fibrillation; VT, ventricular tachycardia.

Table 3

Excess acute CV deaths by cause and place of death

HomeCare home and hospiceHospital
COVID-19 relatedTotalCOVID-19 relatedTotalCOVID-19 relatedTotal*
Stroke22 (+2%)453 (+47%)91 (+5%)715 (+39%)448 (+7%)12 (+0%)
Acute coronary syndrome22 (+1%)768 (+41%)25 (+7%)145 (+41%)269 (+7%)44 (+1%)
Heart failure32 (+1%)734 (+33%)42 (+5%)227 (+25%)198 (+6%)36 (+1%)
Pulmonary embolism18 (+2%)251 (+30%)14 (+6%)49 (+22%)219 (+19%)155 (+13%)
Cardiac arrest14 (+8%)92 (+53%)5 (+250%)11 (+565%)73 (+6%)16 (+1%)
Aortic diseases0 (0%)35 (+7%)0 (0%)0 (+19%)4 (+1%)23 (+3%)
Infective endocarditis1 (+1%)86 (+45%)2 (+15%)12 (+96%)29 (+5%)42 (+8%)
Cardiogenic shock0 (0%)0 (0%)0 (0%)0 (0%)14 (+4%)55 (+15%)
VT and VF0 (0%)1 (+3%)0 (0%)0 (0%)4 (+2%)17 (+9%)
Deep vein thrombosis0 (0%)2 (+7%)0 (0%)0 (0%)2 (+3%)5 (+7%)

*The positive excess rate in hospital was due to setting those daily deaths below the expected historical average to zeros.

CV, cardiovascular; VF, ventricular fibrillation; VT, ventricular tachycardia.

Time series of acute cardiovascular (CV) deaths by cause of death and place of death. The number of daily CV deaths is presented using a 7-day simple moving average (indicating the mean number of daily CV deaths for that day and the preceding 6 days) from 1 February 2020 up to and including 30 June 2020, adjusted for seasonality. The number of non-COVID-19 excess CV deaths each day from 1 February 2020 were subtracted from the expected daily death estimated using Farrington surveillance algorithm in the same time period. The green line is a zero historical baseline. The red line represents excess daily death at hospital; the purple line represents excess daily CV death at care home and hospice and the blue line represents excess daily CV death at home. VF, ventricular fibrillation; VT, ventricular tachycardia. Excess acute CV deaths by cause and place of death *The positive excess rate in hospital was due to setting those daily deaths below the expected historical average to zeros. CV, cardiovascular; VF, ventricular fibrillation; VT, ventricular tachycardia.

Discussion

We show for the first time, in a nationwide complete analysis of all adult deaths, the extent, site and underlying causes of the increased acute CV mortality during the COVID-19 pandemic compared with previous years. This shows that the pandemic has resulted in an abrupt inflation in acute CV deaths above that expected for the time of year. Nearly half of the deaths occurred outside of the hospital setting, either at home or in care homes, with people’s homes witnessing the greatest proportional increase in excess acute CV deaths. The most frequent cause of acute CV death during the COVID-19 pandemic in England and Wales was stroke followed by acute coronary syndrome and heart failure. This is key information to optimise messaging to the public, as well as for allocation of health resources and planning. Numerous international studies have reported the decline in hospital presentations for a range of CV emergencies.6–11 To the best of our knowledge, this is the first study to show that this is associated with an adverse overall CV impact. While stroke and acute coronary syndrome accounted for the vast majority of acute CV deaths, the number of deaths in hospital due to these conditions fell below that expected for the time of year and it increased in the community, and particularly in people’s homes. This ‘displacement of death’, most likely, signifies that the public either did not seek help or were not referred to hospital during the pandemic—a finding supported by the fact that the majority of acute CV deaths were not recorded as related to infection with COVID-19. Given the times series plots show that the excess in acute CV mortality began in late March 2020 and peaked in early April 2020, government directives at the time including the onset of the UK lockdown on 23 March 2020 could have accentuated a maladaptive public response. The major causes of acute CV death were different between hospital and community settings. This ‘differential of cause of death by place’ provides an understanding of how the infection and public response to the pandemic played out. The most frequent cause of excess acute CV death in people’s homes was acute coronary syndrome, in care homes and hospices it was stroke and in hospital it was pulmonary embolism. Assuming that the public did not seek help for medical emergencies for fear of contagion in hospital or to prevent hospitals being overwhelmed, then it is not surprising that there were deaths from acute coronary syndrome at home. Complications of untreated acute myocardial infarction include cardiac arrest, arrhythmia and acute heart failure. We found that in people’s homes there were increases in excess acute CV deaths from cardiac arrest (in line with others’ findings14) and heart failure, and in hospitals there were increases in excess deaths from cardiogenic shock and VT and VF—all of which are complications of late presentation myocardial infarction. In hospital, we also found an inflation of deaths from infective endocarditis and aortic dissection and rupture, indicating perhaps a more advanced (and for some, irreversible) stage of disease presentation during the pandemic, akin to the situation with acute myocardial infarction. Care homes and hospices witnessed a substantial increase in excess acute CV deaths. Herein, stroke, heart failure, acute coronary syndrome and pulmonary embolism were the the most common causes of acute CV death. This finding highlights the susceptibility of the elderly and comorbid to the wider implications of COVID-19 crisis. That is, not only were care home residents prone to the respiratory effects of COVID-19 infection but they will also have been exposed to the acute CV complications of COVID-19 and decisions not to go to hospital for fear of becoming infected. This situation will have been exacerbated by several factors, including the discharge of unknowingly infected patients from hospitals to care homes early in the course of the pandemic (where the virus could easily spread15 and actions to reduce the spread of the virus in social care were too late and insufficient16), a lack of systematic antibody testing for the SARS-CoV-2 virus, the efficient person-to-person transmission of the virus, and its propensity to death in the vulnerable.1 17 While previous reports have described an elevated risk of death among the elderly and people with CV disease during the COVID-19 pandemic, none have characterised the CV events directly leading to death and few quantified the excess in acute CV mortality.1 3 18 To date, insights have been derived from small series of cases, regional or national death records data—each reporting elevated mortality rates, but none by the type and place of CV death together.1 2 18–22 The unique strengths of this investigation include full population coverage of all adult deaths across places of death. Most previous reports have been confined to hospitals deaths and have not captured the full extent of the impact of the pandemic, including deaths outside of hospitals in people who may not have been tested for the disease. Nonetheless, our study has limitations. During the COVID-19 pandemic, emergency guidance enabled any doctor in the UK (not just the attending) to complete the MCCD, the duration of time over which the deceased was not seen before referral to the coroner was extended from 14 to 28 days, and causes of death could be ‘to the best of their knowledge and belief’ without diagnostic proof, if appropriate and to avoid delay.23 This may have resulted in misclassification bias, with under-reporting of the deaths directly due to CV disease in preference to COVID-19 infection (which is a notifiable disease under the Health Protection (Notification) Regulations 2010) or respiratory disease. In fact, we found that MCCDs with COVID-19 certification less frequently contained details of acute CV events directly leading to death. Although the MCCD allows the detailing of the sequence of events directly leading to death, we found that after 2 March 2020 few (5.7%) had multiple acute CV events recorded, and therefore the categorisation of the acute CV events effectively represents per-patient events. The lower proportion of deaths with COVID-19 at home and in care homes may represent the lack of access to community-based COVID-19 testing. Equally, because there was no systematic testing of the UK populace for the presence the COVID-19, deaths associated with the infection may have been underestimated.24 This analysis will have excluded a small proportion of deaths under review by the coroner, though typically these will have been unnatural in aetiology. In addition, we did not include the spatial information in the Farrington surveillance algorithm, which may affect the accuracy of the estimates for the expected death.

Conclusion

To date, there is no whole-population, high temporal resolution information about acute CV-specific mortality during the COVID-19 pandemic. Through the systematic classification of all adult deaths in England and Wales, it has been possible to show that there has been an excess in acute CV mortality during the COVID-19 pandemic, seen greatest in the community and which corresponds with the onset of public messaging and the substantial decline in admissions to hospital with acute CV emergencies. Cardiovascular disease is one of the most prevalent underlying conditions associated with increased mortality from COVID-19 infection, along with dementia and Alzheimer’s disease. At the same time, there has been a substantial reduction in presentations to hospitals with acute cardiovascular (CV) conditions. Our study of all adult deaths in England and Wales between 1 January 2014 and 30 June 2020 has quantified the CV mortality impact of the COVID-19 pandemic, be this related to contagion and/or the public response. It shows that during the pandemic there has been an inflation in acute CV deaths above that expected for the time of year. Home death had the greatest increase in excess acute CV death, and the most frequent cause of acute CV death during this period was stroke, followed by acute coronary syndrome. These contemporary nationwide cause and place of mortality data provide key information to optimise messaging to the public, as well as for allocation of health resources and planning.
  51 in total

1.  The bimodal "rise and fall" ACS curve overlapping COVID-19 pandemic peaks.

Authors:  Daniela Trabattoni; Paolo M Ravagnani; Luca Merlino; Piero Montorsi; Antonio L Bartorelli
Journal:  Am J Cardiovasc Dis       Date:  2021-06-15

2.  Twelfth Interagency Registry for Mechanically Assisted Circulatory Support Report: Readmissions After Left Ventricular Assist Device.

Authors:  Palak Shah; Melana Yuzefpolskaya; Gavin W Hickey; Khadijah Breathett; Omar Wever-Pinzon; Van-Khue Ton; William Hiesinger; Devin Koehl; James K Kirklin; Ryan S Cantor; Jeffrey P Jacobs; Robert H Habib; Francis D Pagani; Daniel J Goldstein
Journal:  Ann Thorac Surg       Date:  2022-01-07       Impact factor: 4.330

3.  Cardiovascular-related deaths at the beginning of the COVID-19 outbreak: a prospective analysis based on the UK Biobank.

Authors:  Fang Fang; Huan Song; Junren Wang; Jianwei Zhu; Huazhen Yang; Yao Hu; Yajing Sun; Zhiye Ying; Yuanyuan Qu; Unnur Valdimarsdottir
Journal:  BMJ Open       Date:  2021-06-04       Impact factor: 3.006

4.  Impact of COVID-19 lockdown on the incidence and mortality of acute exacerbations of chronic obstructive pulmonary disease: national interrupted time series analyses for Scotland and Wales.

Authors:  Mohammad A Alsallakh; Shanya Sivakumaran; Sharon Kennedy; Eleftheria Vasileiou; Ronan A Lyons; Chris Robertson; Aziz Sheikh; Gwyneth A Davies
Journal:  BMC Med       Date:  2021-05-17       Impact factor: 8.775

5.  International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19.

Authors:  Thomas A Kite; Peter F Ludman; Chris P Gale; Jianhua Wu; Adriano Caixeta; Jacques Mansourati; Manel Sabate; Pilar Jimenez-Quevedo; Luciano Candilio; Parham Sadeghipour; Angel M Iniesta; Stephen P Hoole; Nick Palmer; Albert Ariza-Solé; Alim Namitokov; Hector H Escutia-Cuevas; Flavien Vincent; Otilia Tica; Mzee Ngunga; Imad Meray; Andrew Morrow; Md Minhaj Arefin; Steven Lindsay; Ghada Kazamel; Vinoda Sharma; Aly Saad; Gianfranco Sinagra; Federico Ariel Sanchez; Marek Roik; Stefano Savonitto; Marija Vavlukis; Shankar Sangaraju; Iqbal S Malik; Sharon Kean; Nick Curzen; Colin Berry; Gregg W Stone; Bernard J Gersh; Anthony H Gershlick
Journal:  J Am Coll Cardiol       Date:  2021-05-25       Impact factor: 24.094

6.  Improved strategies to counter the COVID-19 pandemic: Lockdowns vs. primary and community healthcare.

Authors:  Konstantinos Farsalinos; Konstantinos Poulas; Dimitrios Kouretas; Apostolos Vantarakis; Michalis Leotsinidis; Dimitrios Kouvelas; Anca Oana Docea; Ronald Kostoff; Grigorios T Gerotziafas; Michael N Antoniou; Riccardo Polosa; Anastastia Barbouni; Vassiliki Yiakoumaki; Theodoros V Giannouchos; Pantelis G Bagos; George Lazopoulos; Boris N Izotov; Victor A Tutelyan; Michael Aschner; Thomas Hartung; Heather M Wallace; Félix Carvalho; Jose L Domingo; Aristides Tsatsakis
Journal:  Toxicol Rep       Date:  2020-12-03

7.  Antibiotic resistance during and beyond COVID-19.

Authors:  David M Livermore
Journal:  JAC Antimicrob Resist       Date:  2021-06-15

8.  Spread of COVID-19 in Zambia: An assessment of environmental and socioeconomic factors using a classification tree approach.

Authors:  Darius Phiri; Serajis Salekin; Vincent R Nyirenda; Matamyo Simwanda; Manjula Ranagalage; Yuji Murayama
Journal:  Sci Afr       Date:  2021-07-05

Review 9.  Air pollution and cardiovascular disease: Can the Australian bushfires and global COVID-19 pandemic of 2020 convince us to change our ways?

Authors:  Kathryn Wolhuter; Manish Arora; Jason C Kovacic
Journal:  Bioessays       Date:  2021-06-09       Impact factor: 4.653

Review 10.  Gastrointestinal and renal complications in SARS-CoV-2-infected patients: Role of immune system.

Authors:  Fatemeh Maghool; Ali Valiani; Tahereh Safari; Mohammad Hassan Emami; Samane Mohammadzadeh
Journal:  Scand J Immunol       Date:  2020-12-07       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.